Navigation Links
Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
Date:8/16/2010

es are useful in evaluating its operating results as this information supplies the user with another view of the matching of costs and expenses. A reconciliation of the adjustments to GAAP results for the three and six month periods ended June 30, 2010 is included below. The non-GAAP information presented is supplemental and is not purported to be a substitute for information prepared in accordance with GAAP.

Non-GAAP financial results for the three and six month periods ended June 30, 2010 discussed in this release reflect operating results excluding the impact of the non-cash, stock-based compensation recognized under general and administrative expenses in connection to deferred compensation and associated investor relation expense related to its private placement financing in January 2010 as well as compensation to four Directors and a key employee.

Safe Harbor Statement

Certain statements in this press release and oral statements made by Weikang Bio-Technology Group Co., Inc. on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports th
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... AB, the Swedish,life science technology company, has ... based on supercritical fluid technology.,The Company,s RightSize ... of traditional micronization and is well suited ... the advantages of earlier supercritical,fluid technologies it ...
... As researchers push towards detection of single molecules, single ... movement, Yale researchers have demonstrated silicon-based nanocantilevers, smaller than ... eliminating the need for electric transducers and expensive laser ... advance online publication of Nature Nanotechnology ushers ...
... CITY, China, April 24 Sinobiopharma, Inc. (OTC Bulletin ... highlights from the unaudited financial results for the nine month period ... , Sales revenue increased to ... US $1,170,677 in the corresponding period ended February 29, 2008. ...
Cached Biology Technology:Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 2Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 3Catching the lightwave: Nano-mechanical sensors 'wired' by photonics 2Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009 2
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
(Date:4/17/2014)... One day about eight years ago, Katia ... Riverside, and her father were on a field trip in ... an orchid they had never seen before. , Unable to ... orchids. The orchid turned out to be an unnamed ... Lophiaris silverarum . , "Lophiaris" is the genus name, comprising ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... a current issue in neuroscience, Aldo Faisal and Simon Laughlin ... transmitting information. They show that noise effects in ion channels ... the fidelity of transmission is compromised. , Neurons in ... density of up to 4km per mm3 by using incredibly ...
... A naturally occurring molecule in the body appears to ... agonists used in acute heart failure or in inhalers ... oxide is a molecule produced by the body that ... blood vessels. , New experiments conducted by Duke ...
... The first clinical trial to test a revolutionary treatment ... at UCL (University College London). The trial, funded by ... kind and could have a significant impact on future ... involves adults and children who have a condition called ...
Cached Biology News:Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3First clinical trial of gene therapy for childhood blindness 2
... Sample Preparation for Membrane Proteins ,Contains ... membrane,protein extracts for 2-D gel analysis ... Extraction Kit , (contains sufficient ... a packed cell weight of 10 mg ...
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
Biology Products: